Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
BDTXCAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs) and outlined plans for a randomized Phase 2 trial of silevertinib in patients with newly diagnosed glioblastoma (ND GBM).
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BDTXCAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
Black Diamond Therapeutic Q1 EPS $0.98 Beats $0.02 Estimate, Sales $70.00M
BDTXBlack Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
BDTXServier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.
Black Diamond Therapeutics And Servier Announce A Global Licensing Agreement For BDTX-4933 For Solid tumors; Servier Will Develop And Commercialize BDTX-4933, Black Diamond To Receive $70M Upfront Payment And Up To $710M In Milestones
BDTXHC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12
BDTXStifel Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $15
BDTXBlack Diamond Therapeutic Q4 EPS $(0.28) Beats $(0.31) Estimate
BDTXHC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
BDTXBlack Diamond Therapeutic's Cash, Cash Equivalents, And Investments Of $112.7M As Of September 30, 2024; Expected To Be Sufficient To Fund Operations Into Q2 Of 2026
BDTXBlack Diamond Therapeutic Q3 2024 GAAP EPS $(0.28) Beats $(0.38) Estimate
BDTXHC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
BDTX